Supplementary Online Content

Similar documents
Supplementary Online Content

CIGARETTE SMOKING IS THE

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

(n=6279). Continuous variables are reported as mean with 95% confidence interval and T1 T2 T3. Number of subjects

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Supplementary Table 1. Baseline Characteristics by Quintiles of Systolic and Diastolic Blood Pressures

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Know Your Number Aggregate Report Comparison Analysis Between Baseline & Follow-up

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and

Table S1. Characteristics associated with frequency of nut consumption (full entire sample; Nn=4,416).

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Physical activity as an aid for smoking cessation

Supplementary Online Content

Supplementary Online Content

Supplementary Material. Serum Chloride is an Independent Predictor of Mortality in Hypertensive Patients

Diabetes, Diet and SMI: How can we make a difference?

Glycemic index, glycemic load, and the risk of acute myocardial infarction in middle-aged Finnish men:

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

National Collaborative Wave 2 (Wave 9): National Diabetes Prevention and Management Wave, Month 9 Diabetes Management: Diabetes Register

Supplementary Online Content

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Varenicline and cardiovascular and neuropsychiatric events: Do Benefits outweigh risks?

Supplemental tables/figures

Declaration of Conflict of Interest. No potential conflict of interest to disclose with regard to the topics of this presentations.

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

DM type. Diagnostic method of DR. fluorescein angiography; Ophthalmoscopy. ophthalmoscopic examination. fundus photography; Ophthalmoscopy

Diabetes Mellitus: A Cardiovascular Disease

SUPPLEMENTAL MATERIAL

AGING KIDNEY IN HIV DISEASE

An example of a systematic review and meta-analysis

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Smoking Status and Body Mass Index in the United States:

Pharmacotherapy for Tobacco Dependence Treatment

Cardiovascular Risk Assessment and Management Making a Difference

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW

Supplementary Online Content

John s Labs & Tests (for December 1, 2012)

Patient is healthy with no chronic disease or significant risk factors [16%].

Supplementary Online Content

CVD Prevention, Who to Consider

Overweight and Obesity in Older Persons: Impact Upon Health and Mortality Outcomes

Supplementary Online Content

5. Cardiovascular Disease & Stroke

Supplementary Online Content

PERCEPTION OF CVD RISK FACTORS BY DIFFERENT STAKEHOLDERS - DOCTORS, MEDICAL STUDENTS, GENERAL PUBLIC, POLITICIANS, JOURNALISTS Professor ŽeljkoReiner,

The Clinical Unmet need in the patient with Diabetes and ACS

MEDCODE READCODE READTERM

Heather Dacus, DO, MPH Preventive Medicine Physician Director, Bureau of Chronic Disease Control New York State Department of Health

ORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults

Supplementary Online Content

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic

Supplementary Online Content

Supplementary Online Content

Supplementary Online Content

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

Reducing CVD globally through combination approaches to prevention: the polypill. Salim Yusuf

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Epidemiologic Measure of Association

Qualification Form Instructions

Understanding new international guidelines to tackle CV Risk: A practical model John Deanfield, MD UCL, London United Kingdom s

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Blood Pressure LIMBO How Low To Go?

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

AHA Clinical Science Special Report: November 10, 2015

Women and Heart Disease : Separating Fact from Fiction

Diabetes and Cardiovascular risk factors among Oil Sector Workers in the State of Kuwait (2013 KOC Periodical Medical Exam.)

Supplementary Online Content

Supplementary Online Content

Update on CVD and Microvascular Complications in T2D

The Gender Divide Women, Men and Heart Disease February 2017

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center

Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea

Effect of Smoking, Alcohol and Exercise on the Prevalence of Metabolic Syndrome in a Cohort of Royal Jordanian Air Pilots

What could a public health strategy for weight loss look like? Paul Aveyard Professor of behavioural medicine

Supplementary Online Content

LDL cholesterol and cardiovascular outcomes?

Supplementary Online Content

Transcription:

Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644. etable 1. Association Between Smoking Cessation, Weight Change, and CVD Events Among Participants With and Without Diabetes With Alternate Smoking Definition etable 2. Association Between Smoking Cessation and CVD Events, Stratified by Weight Gain (Participants With and Without Diabetes Pooled Together) etable 3. Association Between Smoking Cessation, Weight Change, and High Blood Pressure (HBP) Among Participants With and Without Diabetes etable 4. Association Between Smoking Cessation, Weight Change, and Hyperlipidemia Among Participants With and Without Diabetes efigure 1. Weight Change in People With and Without Diabetes Over Time efigure 2. Diabetes Incidence According to Smoking Status Over Time This supplementary material has been provided by the authors to give readers additional information about their work.

etable 1. Association Between Smoking Cessation, Weight Change, and CVD Events Among Participants With and Without Diabetes With Alternate Smoking Definition No diabetes Sustained smokers (ref) Former smokers Never smokers Relapsers* Quitters** Person-exams 1762 330 4187 3389 No. of CVD events 135 17 240 114 Age-, sex-adjusted HR (95% CI) 1 0.55 (0.32-0.95) 0.45 (0.33-0.60) 0.30 (0.21-0.42) HR (95% CI) 1 0.60 (0.35-1.04) 0.46 (0.33-0.63) 0.32 (0.22-0.46) change-adjusted HR (95% CI) 1 0.63 (0.36-1.09) 0.44 (0.32-0.61) 0.29 (0.20-0.42) Diabetes Sustained smokers (ref) Former smokers Never smokers Relapsers* Quitters** Person-exams 260 42 675 503 No. of CVD events 21 2 68 34 Age-, sex-adjusted HR (95% CI) 1 0.23 (0.03-1.75) 0.59 (0.31-1.11) 0.30 (0.21-0.42) HR (95% CI) 1 0.24 (0.03-1.84) 0.56 (0.28-1.11) 0.32 (0.22-0.46) change-adjusted HR (95% CI) 1 0.23 (0.03-1.83) 0.59 (0.29-1.20) 0.29 (0.20-0.42) CVD=cardiovascular disease, HR = Hazard Ratio, CI = Confidence Interval, BMI = body-mass index, ref = reference * Relapsers = participants who alternated between smoking and smoking cessation during the study) ** Quitters = smokers who had made a quit attempts and remained abstinent for the rest of the study Adjusted for age, sex, alcohol consumption, self-reported family history of diabetes, systolic, blood pressure, HDL-cholesterol, LDL-cholesterol, triglycerides, baseline BMI, cholesterol lowering treatment, anti-hypertension treatment

etable 2. Association Between Smoking Cessation and CVD Events, Stratified by Weight Gain (Participants With and Without Diabetes Pooled Together) All participants Lost weight (n=3840 person-exams) Person-exams 754 145 1637 1304 No. of CVD events 69 13 114 65 HR (95% CI) 1 0.42 (0.13-1.37) 0.41 (0.27-0.63) 0.33 (0.21-0.53) Gained 0-5 kg (n=4140 person-exams) Person-exams 786 226 1913 1716 No. of CVD events 69 12 115 58 HR (95% CI) 1 0.34 (0.11-1.12) 0.39 (0.25-0.61) 0.25 (0.15-0.42) Gained 5 kg (n=1971 person-exams) Person-exams 443 197 654 677 No. of CVD events 19 9 39 19 HR (95% CI) 1 1.71 (0.49-5.95) 1.87 (0.71-4.96) 0.96 (0.33-2.84) CVD=cardiovascular disease, HR = Hazard Ratio, CI = Confidence Interval, ref = reference Adjusted for age, sex, alcohol consumption, self-reported family history of diabetes, systolic, blood pressure, HDL-cholesterol, LDL-cholesterol, triglycerides, baseline BMI, cholesterol lowering treatment, anti-hypertension treatment

etable 3. Association Between Smoking Cessation, Weight Change, and High Blood Pressure (HBP) Among Participants With and Without Diabetes No diabetes Person-exams 3055 662 4464 4299 No. of cases of HBP 628 128 1206 865 (95% CI) 1 1.27 (1.00-1.62) 1.17 (1.01-1.34) 1.00 (0.86-1.15) OR (95% CI) 1 1.14 (0.89-1.47) 1.05 (0.91-1.22) 1.03 (0.88-1.20) CI) 1 1.14 (0.89-1.47) 1.05 (0.91-1.22) 1.03 (0.88-1.20) Diabetes Person-exams 487 119 647 515 No. of cases of HBP 195 48 316 258 (95% CI) 1 1.25 (0.78-2.00) 1.18 (0.86-1.61) 1.41 (1.02-1.96) OR (95% CI) 1 1.21 (0.74-1.99) 1.10 (0.79-1.54) 1.39 (0.97-1.99) CI) 1 1.19 (0.73-1.95) 1.10 (0.79-1.54) 1.39 (0.97-1.99) HBP=High blood pressure, OR = Odds Ratio, CI = Confidence Interval, BMI = body-mass index, ref = reference Adjusted for age, sex, alcohol consumption, self-reported family history of diabetes, HDLcholesterol, LDL-cholesterol, triglycerides, baseline BMI, cholesterol lowering treatment

etable 4. Association Between Smoking Cessation, Weight Change, and Hyperlipidemia Among Participants With and Without Diabetes No diabetes Person-exams 2559 566 3514 3698 No. of cases of hyperlipidemia 444 80 477 462 (95% CI) 1 0.50 (0.20-1.27) 0.97 (0.58-1.62) 0.89 (0.52-1.52) OR (95% CI) 1 0.50 (0.19-1.30) 0.96 (0.57-1.63) 0.90 (0.51-1.59) CI) 1 0.53 (0.20-1.37) 0.97 (0.57-1.65) 0.92 (0.52-1.62) Diabetes Person-exams 361 99 543 455 No. of cases of hyperlipidemia 49 7 77 59 (95% CI) 1 0.94 (0.70-1.24) 0.80 (0.68-0.96) 0.72 (0.61-0.86) OR (95% CI) 1 1.12 (0.80-1.58) 0.96 (0.78-1.18) 0.85 (0.69-1.06) CI) 1 1.12 (0.79-1.57) 0.96 (0.78-1.18) 0.86 (0.69-1.06) OR = Odds Ratio, CI = Confidence Interval, BMI = body-mass index, ref = reference Adjusted for age, sex, alcohol consumption, self-reported family history of diabetes, systolic, blood pressure, baseline HDL-cholesterol, baseline LDL-cholesterol, baseline triglycerides, baseline BMI

efigure 1: Weight Change in People With And Without Diabetes Over Time Participants Without Diabetes

efigure 1 (Cont d) Participants With Diabetes